AV 513
Alternative Names: AV513Latest Information Update: 08 Mar 2011
Price :
$50 *
At a glance
- Originator Avigen
- Developer Baxter Healthcare Corporation
- Class Antihaemorrhagics; Coagulants; Polysaccharides; Small molecules
- Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia A; Haemophilia B